Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734014 | 0.74 | CYP2C19 (0.47) | ALDH1A1CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL8166900 | 0.72 | ALDH1A1 (0.41) | ALDH1A1CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL8166897 | 0.72 | ALDH1A1 (0.43) | ALDH1A1CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL8941120 | 0.71 | CA2 (0.53) | — | |
| SCHEMBL25771 | 0.70 | ALDH1A1 (0.45) | ALDH1A1CYP2C19MAPTKMT2ATDP1 | |
| SCHEMBL1144951 | 0.70 | ATAD2 (0.39) | — | |
| SCHEMBL17682900 | 0.68 | ATAD2 (0.42) | — | |
| SCHEMBL9227461 | 0.68 | ALDH1A1 (0.45) | ALDH1A1CYP2C19MAPTKDM4EKMT2A | |
| SCHEMBL8505313 | 0.67 | CYP2C19 (0.50) | ALDH1A1CYP2C19MAPTKDM4EKMT2A | |
| SCHEMBL30753113 | 0.66 | MEN1 (0.44) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1041159-A2 | Method, oligonucleotides suitable for the degradation of in vitro synthesized nucleic acid molecules | MIRA Diagnostika GmbH (DE) | 2000-10-04 | — | — | EP | claimed |
| WO-1999050447-A1 | METHOD AND NUCLEIC ACID COMPOUND FOR BREAKING DOWN NUCLEIC ACID MOLECULES SYNTHESIZED $i(IN VITRO) | MIRA DIAGNOSTIKA GMBH (DE) | 1999-10-07 | — | — | WO | claimed |
| EP-1041159-A2 | Method, oligonucleotides suitable for the degradation of in vitro synthesized nucleic acid molecules | MIRA Diagnostika GmbH (DE) | 2000-10-04 | — | — | EP | disclosed |
| EP-1038974-A1 | Method, oligonucleotides suitable for the degradation of in vitro synthezised nucleic acid molecules | Mira Diagnostica GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999050447-A1 | METHOD AND NUCLEIC ACID COMPOUND FOR BREAKING DOWN NUCLEIC ACID MOLECULES SYNTHESIZED $i(IN VITRO) | MIRA DIAGNOSTIKA GMBH (DE) | 1999-10-07 | — | — | WO | disclosed |